Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Akcea Therapeutics Inc (NASDAQ:AKCA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,500 shares of the company’s stock, valued at approximately $180,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new stake in Akcea Therapeutics in the 3rd quarter valued at approximately $1,413,000. Rhumbline Advisers acquired a new stake in Akcea Therapeutics in the 3rd quarter valued at approximately $353,000. New York State Common Retirement Fund acquired a new stake in Akcea Therapeutics in the 3rd quarter valued at approximately $810,000. Candriam Luxembourg S.C.A. acquired a new stake in Akcea Therapeutics in the 3rd quarter valued at approximately $5,314,000. Finally, Nationwide Fund Advisors acquired a new stake in Akcea Therapeutics in the 3rd quarter valued at approximately $209,000. Hedge funds and other institutional investors own 26.04% of the company’s stock.

Akcea Therapeutics Inc (AKCA) opened at $17.42 on Thursday. Akcea Therapeutics Inc has a one year low of $8.10 and a one year high of $31.23.

Several analysts recently commented on AKCA shares. Cowen restated a “buy” rating on shares of Akcea Therapeutics in a research report on Tuesday, October 31st. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target (up from $19.00) on shares of Akcea Therapeutics in a research note on Tuesday, November 7th. Finally, Zacks Investment Research lowered Akcea Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Akcea Therapeutics currently has an average rating of “Buy” and an average target price of $24.00.

TRADEMARK VIOLATION NOTICE: “6,500 Shares in Akcea Therapeutics Inc (AKCA) Acquired by Zurcher Kantonalbank Zurich Cantonalbank” was posted by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/6500-shares-in-akcea-therapeutics-inc-akca-acquired-by-zurcher-kantonalbank-zurich-cantonalbank/1748731.html.

Akcea Therapeutics Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Ratings for Akcea Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.